Literature DB >> 1888627

Should we cross off the crossover?

P Armitage.   

Abstract

Mesh：

Year:  1991        PMID： 1888627      PMCID： PMC1368484          DOI： 10.1111/j.1365-2125.1991.tb05604.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  7 in total

1.  THE TWO-PERIOD CHANGE-OVER DESIGN AN ITS USE IN CLINICAL TRIALS.

Authors:  J E GRIZZLE
Journal:  Biometrics       Date:  1965-06       Impact factor: 2.571

2.  A graphical presentation of the results of crossover trials.

Authors:  T A Sheldon
Journal:  Br J Clin Pharmacol       Date:  1990-09       Impact factor: 4.335

3.  Subgroup analyses.

Authors:  D A Berry
Journal:  Biometrics       Date:  1990-12       Impact factor: 2.571

4.  Problems with the two stage analysis of crossover trials.

Authors:  S J Senn
Journal:  Br J Clin Pharmacol       Date:  1991-07       Impact factor: 4.335

5.  The performance of the two-stage analysis of two-treatment, two-period crossover trials.

Authors:  P R Freeman
Journal:  Stat Med       Date:  1989-12       Impact factor: 2.373

6.  Cross-over trials, carry-over effects and the art of self-delusion.

Authors:  S J Senn
Journal:  Stat Med       Date:  1988-10       Impact factor: 2.373

7.  The two-period cross-over clinical trial.

Authors:  M Hills; P Armitage
Journal:  Br J Clin Pharmacol       Date:  1979-07       Impact factor: 4.335
  7 in total
  10 in total

Review 1.  Anticholinergics for neuroleptic-induced acute akathisia.

Authors:  J Rathbone; K Soares-Weiser
Journal:  Cochrane Database Syst Rev       Date:  2006-10-18

Review 2.  Benzodiazepines for neuroleptic-induced acute akathisia.

Authors:  A R Lima; K Soares-Weiser; J Bacaltchuk; T R Barnes
Journal:  Cochrane Database Syst Rev       Date:  2002

Review 3.  Central action beta-blockers versus placebo for neuroleptic-induced acute akathisia.

Authors:  A R Lima; J Bacalcthuk; T R E Barnes; K Soares-Weiser
Journal:  Cochrane Database Syst Rev       Date:  2004-10-18

Review 4.  Calcium channel blockers for antipsychotic-induced tardive dyskinesia.

Authors:  Adib Essali; Karla Soares-Weiser; Hanna Bergman; Clive E Adams
Journal:  Cochrane Database Syst Rev       Date:  2018-03-26

Review 5.  Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia.

Authors:  Hanna Bergman; John Rathbone; Vivek Agarwal; Karla Soares-Weiser
Journal:  Cochrane Database Syst Rev       Date:  2018-02-06

Review 6.  Anticholinergic medication for antipsychotic-induced tardive dyskinesia.

Authors:  Hanna Bergman; Karla Soares-Weiser
Journal:  Cochrane Database Syst Rev       Date:  2018-01-17

Review 7.  Miscellaneous treatments for antipsychotic-induced tardive dyskinesia.

Authors:  Karla Soares-Weiser; John Rathbone; Yusuke Ogawa; Kiyomi Shinohara; Hanna Bergman
Journal:  Cochrane Database Syst Rev       Date:  2018-03-19

Review 8.  Cholinergic medication for antipsychotic-induced tardive dyskinesia.

Authors:  Irina Tammenmaa-Aho; Rosie Asher; Karla Soares-Weiser; Hanna Bergman
Journal:  Cochrane Database Syst Rev       Date:  2018-03-19

Review 9.  Vitamin E for antipsychotic-induced tardive dyskinesia.

Authors:  Karla Soares-Weiser; Nicola Maayan; Hanna Bergman
Journal:  Cochrane Database Syst Rev       Date:  2018-01-17

Review 10.  Non-antipsychotic catecholaminergic drugs for antipsychotic-induced tardive dyskinesia.

Authors:  Hany G El-Sayeh; John Rathbone; Karla Soares-Weiser; Hanna Bergman
Journal:  Cochrane Database Syst Rev       Date:  2018-01-18
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.